Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance
1 other identifier
interventional
460
1 country
1
Brief Summary
Many patients report residual depressive symptoms despite seemingly successful treatment. With the investigators' previous funding, we developed - Mindful Mood Balance - an online treatment that targets RDS by teaching specific emotion regulation and depression self-management skills that are entirely compatible with antidepressant treatment. The investigators now propose a controlled study to determine whether MMB is more effective than usual care at reducing RDS and other key outcomes. If successful, MMB's online delivery format would provide high fidelity and low-cost empirically supported management of residual symptoms, leading to more robust remission, improved functioning and sustained recovery from MDD over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 10, 2014
CompletedFirst Posted
Study publicly available on registry
July 15, 2014
CompletedStudy Start
First participant enrolled
March 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2018
CompletedJanuary 28, 2019
January 1, 2019
3.7 years
July 10, 2014
January 24, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Patient Health Questionnaire-9
Changes in self reported depressive symptom severity
Change from Baseline to 12 weeks and 15 months
Patient Health Questionnaire-9
Rates of depressive relapse, defined as patients who score 15 or greater on the PHQ-9
Between 12 weeks and 15 months
Patient Health Questionnaire-9
Conversion from moderate/high risk to low risk symptom categories, defined as a patient whose PHQ-9 score drops from a baseline PHQ-9 score between 5 and 9 to a mean score of 4 or less
Between baseline to 12 weeks.
Secondary Outcomes (4)
Ruminative Responses Scale
Change from Baseline to 6 weeks, 12 weeks and 15 months
Five Facet Mindfulness Questionnaire
Change from Baseline to 6 weeks, 12 weeks and 15 months
Five Facet Mindfulness Scale
Change from Baseline to 6 weeks, 12 weeks and 15 months
Experiences Questionnaire
Change from Baseline to 6 weeks, 12 weeks and 15 months
Other Outcomes (4)
Depression Free Days
Change from Baseline to 12 weeks and 15 months
Generalized Anxiety Disorder Assessment - 7
Change from Baseline to 12 weeks and 15 months
Short Form Health Survey - 12
Change from Baseline to 12 weeks and 15 months
- +1 more other outcomes
Study Arms (2)
Mindful Mood Balance
EXPERIMENTALAn 8 session internet intervention targeting residual depressive symptoms.
Usual Depression Care
ACTIVE COMPARATORUsual Depression Care through Kaiser Permanente Colorado
Interventions
Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
Eligibility Criteria
You may qualify if:
- Patients with a PHQ-9 score between 5 and 9
- At least one prior episode of MDD
You may not qualify if:
- presence of schizophrenia or current psychosis, organic mental disorder or pervasive developmental delay
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Torontolead
- University of Colorado, Bouldercollaborator
- Kaiser Permanentecollaborator
Study Sites (1)
Kaiser Permanente Institute for Health Research
Denver, Colorado, 80237-8066, United States
Related Publications (5)
Boggs JM, Beck A, Felder JN, Dimidjian S, Metcalf CA, Segal ZV. Web-based intervention in mindfulness meditation for reducing residual depressive symptoms and relapse prophylaxis: a qualitative study. J Med Internet Res. 2014 Mar 24;16(3):e87. doi: 10.2196/jmir.3129.
PMID: 24662625BACKGROUNDSegal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Bloch R, Levitan RD. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry. 2010 Dec;67(12):1256-64. doi: 10.1001/archgenpsychiatry.2010.168.
PMID: 21135325BACKGROUNDDimidjian S, Beck A, Felder JN, Boggs JM, Gallop R, Segal ZV. Web-based Mindfulness-based Cognitive Therapy for reducing residual depressive symptoms: An open trial and quasi-experimental comparison to propensity score matched controls. Behav Res Ther. 2014 Dec;63:83-9. doi: 10.1016/j.brat.2014.09.004. Epub 2014 Sep 18.
PMID: 25461782BACKGROUNDBoggs JM, Ritzwoller DP, Beck A, Dimidjian S, Segal ZV. Cost-Effectiveness of a Web-Based Program for Residual Depressive Symptoms: Mindful Mood Balance. Psychiatr Serv. 2022 Feb 1;73(2):158-164. doi: 10.1176/appi.ps.202000419. Epub 2021 Jul 29.
PMID: 34320822DERIVEDSegal ZV, Dimidjian S, Beck A, Boggs JM, Vanderkruik R, Metcalf CA, Gallop R, Felder JN, Levy J. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Jun 1;77(6):563-573. doi: 10.1001/jamapsychiatry.2019.4693.
PMID: 31995132DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zindel V Segal, PhD
University of Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 10, 2014
First Posted
July 15, 2014
Study Start
March 1, 2015
Primary Completion
November 1, 2018
Study Completion
November 1, 2018
Last Updated
January 28, 2019
Record last verified: 2019-01